GHRP-6

PeptideXpo buyer fit

Overview

GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family, distinguishable from its siblings (GHRP-2, Ipamorelin, Hexarelin) by its particular feature of producing robust appetite stimulation in addition to GH release. The appetite effect comes from GHRP-6's ghrelin-pathway activation at the hypothalamic-arcuate nucleus level, ghrelin is the endogenous appetite-stimulating hormone, and GHSR agonists at higher doses recapitulate part of ghrelin's appetite-driving activity. In research contexts, GHRP-6 is studied both for GH-release pharmacology and for orexigenic (appetite-stimulating) applications, making it the GHRP-family member most relevant to research workflows that want both effects rather than just one. PeptideXpo supplies GHRP-6 as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide is straightforward to synthesize and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows specifically studying appetite-pharmacology, GHRP-6 is the most appropriate member of the GHRP family; for cleaner GH-selective work, Ipamorelin is preferred to avoid the appetite-and-cortisol confounders.

Who buys this, and why

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

87616-84-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 1.9 minutes

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Counter-ion (acetate vs TFA)
• Sterile-fill release pack (sterility, CCI, fill-weight)
• Bacterial endotoxin (LAL, USP <85>)
• Stability data on request
• SDS / MSDS

Regulatory note

Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
2. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128(4):2027-2035.
3. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab. 1995;80(3):942-947.
4. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.
5. Micic D, Casabiell X, Gualillo O, Pombo M, Dieguez C, Casanueva FF. Growth hormone secretagogues: the clinical future. Horm Res. 1999;51(Suppl 3):29-33.
6. Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46.

Frequently asked questions